Small-cap pharma stock Sigachi Industries jumps after CARE reaffirms credit rating

Small-cap pharma stock Sigachi Industries gained over 2 per cent in intra-day trade on Friday, January 3, after CARE Ratings reaffirmed its rating action on the company.

In an exchange filing on Friday, the company informed that CARE Ratings Limited reaffirmed its rating on the long-term and short-term bank facilities. CARE has assigned CARE A-; Stable to Rs 75.38 crore long-term bank facilities and CARE A-; Stable / CARE A2 to Rs 51.75 crore long-term / short-term bank facilities, respectively.

The rating agency reaffirmed its action following recent developments, including the operational and financial performance of the Sigachi Industries for FY24 and H1-FY25, and the possible impact of the same on the credit profile of your company, CARE said.

Stock Impact

Sigachi Industries, part of the BSE Smallcap index, witnessed a 2.02 per cent increase in its share price to Rs 51.49 apiece.

Sigachi Industries share price opened at 50.48, slightly higher than the previous close of Rs 50.47 apiece. It then extended gains to hit the day’s high of Rs 51.49.

Despite today’s gains, Sigachi Industries have fared poorly in the last one year, eroding investor wealth by 14 per cent. Even in the last one month alone, the stock has lost 5 per cent.

Sigachi Industries stock is almost 90 per cent away from its 52-week high of Rs 95.94 touched in February 2024.

For the second quarter of the financial year 2024-25 (Q2FY25), the company witnessed a 38.10 per cent year-on-year rise in revenue from operations to Rs 137 crore while its profit after tax (PAT) jumped 39% YoY to Rs 21 crore.

The earnings before interest, tax, depreciation and amortisation (Ebitda) margins witnessed a 19 bps growth YoY to 21.38 per cent while PAT margins improved by 159 bps to 16.81%.

Incorporated in 1989, Sigachi Industries operates in the pharmaceutical industry, with a presence in Active Pharmaceutical Ingredients (APIs), Food and Nutrition, Operations & Management, and the Personal Care industry.

Related Posts

Pune FDA busts interstate counterfeit drug racket

Acting on a tip-off, FDA teams seized counterfeit Trypsin-Chymotrypsin tablets, marketed as Chymoral Forte, worth ₹2.75 lakh from the Pune market. Pune:  The Food and Drug Administration (FDA), Pune region,…

Tramadol, Alprazolam Racket: ED Arrests Pharma Dealer for Diverting Psychotropic Drugs, Laundering Rs 3.75 Cr

New Delhi: In a major crackdown on drug-linked money laundering, the Enforcement Directorate (ED) has arrested a pharmaceutical businessman accused of siphoning off nearly 75% of his psychotropic drug stock…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pune FDA busts interstate counterfeit drug racket

Pune FDA busts interstate counterfeit drug racket

Tramadol, Alprazolam Racket: ED Arrests Pharma Dealer for Diverting Psychotropic Drugs, Laundering Rs 3.75 Cr

Tramadol, Alprazolam Racket: ED Arrests Pharma Dealer for Diverting Psychotropic Drugs, Laundering Rs 3.75 Cr

Medicines manufactured without license seized in Himachal Pradesh

Medicines manufactured without license seized in Himachal Pradesh

Report for Building Road to Ultimate Healthcare Assurance in Approaching Vikshit Bharat

Report for Building Road to Ultimate Healthcare Assurance in Approaching Vikshit Bharat

SSI Mantra is making Robotic Surgery Affordable for All – Dr Sangita Reddy

SSI Mantra is making Robotic Surgery Affordable for All – Dr Sangita Reddy

Govt cracks down on erring pharma units

Govt cracks down on erring pharma units